CA2562992A1 - Probucol analogues, and use thereof as anti-inflammatory inhibitors of vcam-1 - Google Patents
Probucol analogues, and use thereof as anti-inflammatory inhibitors of vcam-1 Download PDFInfo
- Publication number
- CA2562992A1 CA2562992A1 CA002562992A CA2562992A CA2562992A1 CA 2562992 A1 CA2562992 A1 CA 2562992A1 CA 002562992 A CA002562992 A CA 002562992A CA 2562992 A CA2562992 A CA 2562992A CA 2562992 A1 CA2562992 A1 CA 2562992A1
- Authority
- CA
- Canada
- Prior art keywords
- butyl
- compound
- treatment
- pharmaceutically acceptable
- disease mediated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
Claims (123)
1) A compound of the formula (I):
characterized in that:
a) R a and R b are C1-6 alkyl, and R c and R d are H or C1-6 alkyl;
b) Z is a pyranose group; -(CH2)-R e;
c) R e is OH; NH2; COOH; epoxy; di(C1-6)alkylamino; or C1-6 alkyl optionally substituted with OH, COC)H, C1-6 alkoxycarbonyl substituted C2-7 alkenyl, or di-C1-6 alkylamino substituted phenyl-C1-4 alkyl;
or its pharmaceutically acceptable salt.
characterized in that:
a) R a and R b are C1-6 alkyl, and R c and R d are H or C1-6 alkyl;
b) Z is a pyranose group; -(CH2)-R e;
c) R e is OH; NH2; COOH; epoxy; di(C1-6)alkylamino; or C1-6 alkyl optionally substituted with OH, COC)H, C1-6 alkoxycarbonyl substituted C2-7 alkenyl, or di-C1-6 alkylamino substituted phenyl-C1-4 alkyl;
or its pharmaceutically acceptable salt.
2) The compound of claim 1, wherein R a, R b, R c and R d are t-butyl.
3) The compound of claim 1 or 2, wherein Z is -(CH2)-R e.
4) The compound of claim 1 or 2, wherein Z is -(CH2)-R e and R e is polyhydroxy-substituted C1-C6 alkyl.
5) The compound of claim 1 or 2, wherein Z is -(CH2)-R e, and R e is C1-C6 alkyl optionally substituted with carboxy or hydroxyl.
6) The compound of claim 1 or 2, wherein Z is -(CH2)-R e, and R e is C1-C6 alkyl optionally substituted with carboxy.
7) A compound of formula (I):
selected from:
a) R a=1-methylethyl, R b=t-butyl, R c=methyl, R d=methyl, and Z=4-aminobutyl;
b) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-aminobutyl;
c) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=t-butylcarbonyloxymethyl;
d) R a=t-butyl, R b=t-butyl, R c=H, R d=H, and Z=4-aminobutyl;
e) R a=t-butyl, R b=t-butyl, R c=H, R d=H, and Z=3-carboxypropyl;
f) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-2-oxiranyl-ethyl;
g) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-hydroxymethyloxirany-2-ylmethyl;
h) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-(2-hydroxy-2-oxiranyl)ethoxyoxiran-2-ylmethyl; or i) R a t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=oxiranylmethyl.
selected from:
a) R a=1-methylethyl, R b=t-butyl, R c=methyl, R d=methyl, and Z=4-aminobutyl;
b) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-aminobutyl;
c) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=t-butylcarbonyloxymethyl;
d) R a=t-butyl, R b=t-butyl, R c=H, R d=H, and Z=4-aminobutyl;
e) R a=t-butyl, R b=t-butyl, R c=H, R d=H, and Z=3-carboxypropyl;
f) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-2-oxiranyl-ethyl;
g) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-hydroxymethyloxirany-2-ylmethyl;
h) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-(2-hydroxy-2-oxiranyl)ethoxyoxiran-2-ylmethyl; or i) R a t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=oxiranylmethyl.
8) A compound of formula (I):
selected from:
a) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-3-carboxymethylaminopropyl;
b) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-3-ethoxypropyl;
c) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2,3-dihydroxypropyl;
d) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=ethyl;
e) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-ethoxycarbonylethenyl;
f) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-N,N-dimethylaminophenethyl;
g) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-methoxycarbonylpropyl;
h) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-carboxyethenyl;
or i) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=galactopyranosylmethyl.
selected from:
a) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-3-carboxymethylaminopropyl;
b) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-3-ethoxypropyl;
c) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2,3-dihydroxypropyl;
d) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=ethyl;
e) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-ethoxycarbonylethenyl;
f) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-N,N-dimethylaminophenethyl;
g) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-methoxycarbonylpropyl;
h) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-carboxyethenyl;
or i) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=galactopyranosylmethyl.
9) A compound of formula (I):
selected from:
a) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-(N-N-diethylamino)propyl;
b) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-ethoxycarbonylethenyl;
c) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2,3-dihydroxy-4-carboxymethylaminobutyl;
d) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-3-(5-amino-5-carboxy)propylaminopropyl;
e) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-ethylcarbonyloxybutyl;
f) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-hydroxybutyl;
g) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=glucopyranosylmethyl;
h) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=3-hydroxypropenyl;
and i) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=CH2CONH-(CH2)CH(NH2)COOH.
selected from:
a) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=3-(N-N-diethylamino)propyl;
b) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-ethoxycarbonylethenyl;
c) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2,3-dihydroxy-4-carboxymethylaminobutyl;
d) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=2-hydroxy-3-(5-amino-5-carboxy)propylaminopropyl;
e) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-ethylcarbonyloxybutyl;
f) R a=t-butyl, R b=t-butyl, R c=t-butyl, R d=t-butyl, and Z=4-hydroxybutyl;
g) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=glucopyranosylmethyl;
h) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=3-hydroxypropenyl;
and i) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=CH2CONH-(CH2)CH(NH2)COOH.
10) A compound of formula (I):
selected from:
a) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=CH2CONHCH(COOCH2CH3)CH1CH2(COOCH2CH3);
b) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=2-hydroxy-3-acetoxypropyl;
c) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=2-acetoxy-3-hydroxypropyl;
d) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=carboxymethylaminocarbonylmethyl;
e) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, and Rd=t-butyl; and Z=3-carboxypropyl;
or f) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=1,3-dicarboxypropylaminocarbonylmethyl.
selected from:
a) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=CH2CONHCH(COOCH2CH3)CH1CH2(COOCH2CH3);
b) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=2-hydroxy-3-acetoxypropyl;
c) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=2-acetoxy-3-hydroxypropyl;
d) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=carboxymethylaminocarbonylmethyl;
e) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, and Rd=t-butyl; and Z=3-carboxypropyl;
or f) Ra=t-butyl, Rb=t-butyl, Rc=t-butyl, Rd=t-butyl, and Z=1,3-dicarboxypropylaminocarbonylmethyl.
11) A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
12) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
13) A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
14) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
15) A compound of the following fonmula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
16) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
17) A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
18) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
19) A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
20) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
21 ) A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
22) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
23) A compound of the following formula:
or a pharmaceutically acceptable salt or ester thereof.
or a pharmaceutically acceptable salt or ester thereof.
24) A pharmaceutical composition comprising an effective treatment amount of a compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent.
25) The composition of claim 24 suitable for oral administration.
26) The composition of claim 24 suitable for topical or transdermal administration.
27) The composition of claim 24 suitable for parenteral, intravenous, subcutaneous, intraperitoneal, or intramuscular administration.
28) The composition of claim 24 suitable for submucosal administration.
29) The composition of claim 24 suitable for inhalation administration.
30) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of an inflammatory disorder.
31) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by VCAM-1.
32) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of rheumatoid arthritis.
33) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of arthritis.
34) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of a cardiovascular disease.
35) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by a redox sensitive gene.
36) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by MCP-1.
37) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by IL-6.
38) A pharmaceutical composition comprising the compound as defined in any one of claims 1-23 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by thrombin receptor.
39) A pharmaceutical composition comprising an effective treatment amount of a compound of claim 11 and a pharmaceutically acceptable carrier or diluent.
40) The composition of claim 39 suitable for oral administration.
41) The composition of claim 39 suitable for topical or transdermal administration.
42) The composition of claim 39 suitable for parenteral, intravenous, subcutaneous, intraperitoneal, or intramuscular administration.
43) The composition of claim 39 suitable for intravenous administration.
44) The composition of claim 39 suitable for submucosal administration.
45) The composition of claim 39 suitable for inhalation administration.
46) A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier or diluent, for the treatment of an inflammatory disorder.
47) A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier or diluent, for the treatment of a cardiovascular disease.
48) A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically acceptable earner or diluent, for the treatment of a disease mediated by VCAM-1.
49) A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier or diluent, for the treatment of rheumatoid arthritis.
50) A pharmaceutical composition comprising the compound of claims 11 and a pharmaceutically acceptable carrier or diluent, for the treatment of arthritis.
51) A pharmaceutical composition comprising the compound of claims 11 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by a redox sensitive gene.
52) A pharmaceutical composition comprising the compound of claims 11 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by MCP-1.
53) A pharmaceutical composition comprising the compound of claims 11 and a pharmaceutically acceptable earner or diluent, for the treatment of a disease mediated by IL-6.
54) A pharmaceutical composition comprising the compound of claims 11 and a pharmaceutically acceptable earner or diluent, for the treatment of a disease mediated by thrombin receptor.
55) A pharmaceutical composition comprising an effective treatment amount of a compound of claim 13 and a pharmaceutically acceptable carrier or diluent.
56) The composition of claim 55 suitable for oral administration.
57) The composition of claim 55 suitable for topical or transdermal administration.
58) The composition of claim 55 suitable for parenteral, intravenous, subcutaneous, intraperitoneal, or intramuscular administration.
59) The composition of claim 55 suitable for submucosal administration.
60) The composition of claim 55 suitable for inhalation administration.
61) A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of an inflammatory disorder.
62) A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of a cardiovascular disease.
63) A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by VCAM-1.
64) A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of rheumatoid arthritis.
65) A pharmaceutical composition comprising the compound of claims 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of arthritis.
66) A pharmaceutical composition comprising the compound of claims 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by a redox sensitive gene.
67) A pharmaceutical composition comprising the compound of claims 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by MCP-1.
68) A pharmaceutical composition comprising the compound of claims 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by IL-6.
69) A pharmaceutical composition comprising the compound of claims 13 and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease mediated by thrombin receptor.
70) Use of a therapeutically effective amount of the compound according to any one of claims 1-23, for the treatment of an inflammatory disorder, in a subject in need of such therapy.
71 ) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of a disease mediated by VCAM-1, in a subject in need of such therapy.
72) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of rheumatoid arthritis, in a subject in need of such therapy.
73) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of arthritis, in a subject in need of such therapy.
74) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of a cardiovascular disease, in a subject in need of such therapy.
75) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of a disease mediated by a redox sensitive gene, in a subject in need of such therapy.
76) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of a disease mediated by MCP-1, in a subject in need of such therapy.
77) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of a disease mediated by IL-6, in a subject in need of such therapy.
78) Use of a therapeutically effective amount of the compound as defined in any one of claims 1-23, for the treatment of a disease mediated by thrombin receptor, in a subject in need of such therapy.
79) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of an inflammatory disorder, in a subject in need of such therapy.
80) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of a disease mediated by VCAM-1, in a subject in need of such therapy.
81) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of rheumatoid arthritis, in a subject in need of such therapy.
82) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of arthritis, in a subject in need of such therapy.
83) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of a cardiovascular disease, in a subject in need of such therapy.
84) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of a disease mediated by a redox sensitive gene, in a subject in need of such therapy.
85) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of a disease mediated by MCP-1, in a subject in need of such therapy.
86) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of a disease mediated by IL-6, in a subject in need of such therapy.
87) Use of a therapeutically effective amount of the compound as defined in claim 11, for the treatment of a disease mediated by thrombin receptor, in a subject in need of such therapy.
88) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of an inflammatory disorder, in a subject in need of such therapy.
89) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of a disease mediated by VCAM-1, in a subject in need of such therapy.
90) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of rheumatoid arthritis, in a subject in need of such therapy.
91) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of arthritis, in a subject in need of such therapy.
92) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of a cardiovascular disease, in a subject in need of such therapy.
93) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of a disease mediated by a redox sensitive gene, in a subject in need of such therapy.
94) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of a disease mediated by MCP-1, in a subject in need of such therapy.
95) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of a disease mediated by IL-6, in a subject in need of such therapy.
96) Use of a therapeutically effective amount of the compound as defined in claim 13, for the treatment of a disease mediated by thrombin receptor, in a subject in need of such therapy.
97) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of an inflammatory disorder.
98) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of a disease mediated by VCAM-1.
99) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of rheumatoid arthritis.
100) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of arthritis.
101) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of a cardiovascular disease.
102) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of a disease mediated by a redox sensitive gene.
103) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of a disease mediated by MCP-1.
104) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of a disease mediated by IL-6.
105) Use of the compound as defined in any one of claims 1-23 in the manufacture of a medicament for the treatment of a disease mediated by thrombin receptor.
106) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of an inflammatory disorder.
107) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of a disease mediated by VCAM-1.
108) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of rheumatoid arthritis.
109) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of arthritis.
110) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of a cardiovascular disease.
111) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of a disease mediated by a redox sensitive gene.
112) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of a disease mediated by MCP-1.
113) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of a disease mediated by IL-6.
114) Use of the compound as defined in claim 11 in the manufacture of a medicament for the treatment of a disease mediated by thrombin receptor.
115) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of an inflammatory disorder.
116) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of a disease mediated by VCAM-1.
117) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of rheumatoid arthritis.
118) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of arthritis.
119) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of a cardiovascular disease.
120) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of a disease mediated by a redox sensitive gene.
121) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of a disease mediated by MCP-1.
122) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of a disease mediated by IL-6.
123) Use of the compound as defined in claim 13 in the manufacture of a medicament for the treatment of a disease mediated by thrombin receptor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4702097P | 1997-05-14 | 1997-05-14 | |
| US60/047,020 | 1997-05-14 | ||
| CA002289851A CA2289851C (en) | 1997-05-14 | 1998-05-14 | Compounds and methods for the inhibition of the expression of vcam-1 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002289851A Division CA2289851C (en) | 1997-05-14 | 1998-05-14 | Compounds and methods for the inhibition of the expression of vcam-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2562992A1 true CA2562992A1 (en) | 1998-11-19 |
| CA2562992C CA2562992C (en) | 2010-09-28 |
Family
ID=37682471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2562992A Expired - Fee Related CA2562992C (en) | 1997-05-14 | 1998-05-14 | Probucol analogues, and use thereof as anti-inflammatory inhibitors of vcam-1 |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2562992C (en) |
-
1998
- 1998-05-14 CA CA2562992A patent/CA2562992C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2562992C (en) | 2010-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008106058A (en) | Pyridazinone derivatives as thyroid hormone receptor agonists | |
| US7858650B2 (en) | Medicinal composition for inhalation | |
| US20050119305A1 (en) | Il-6 production inhibitors | |
| HUP0104666A2 (en) | Thyroid receptor ligands | |
| CA2526534A1 (en) | Compounds and methods for delivery of prostacyclin analogs | |
| JPH06508135A (en) | Substituted N-carboxyalkyl peptidyl derivatives as anti-denaturing active agents | |
| EA002033B1 (en) | Nitric oxide synthase inhibitors | |
| US6720445B2 (en) | Acetyloxymethyl esters and methods for using the same | |
| MY139577A (en) | Anti-inflammatory androstane derivative | |
| LV12766A (en) | Composition of l-dopa esters | |
| CA2465117A1 (en) | Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases | |
| WO2003030834A3 (en) | Cyclosporin analogs for the treatment of lung diseases | |
| JP2004501189A5 (en) | ||
| ES2489265T3 (en) | Association of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory lung diseases | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| RU95106675A (en) | 3-indolyl piperidines, process for preparation thereof, pharmaceutical composition, and process for preparation thereof | |
| TW201912153A (en) | Compounds, compositions and methods for treating hepatitis b | |
| JP2006511445A (en) | Naphthalene derivatives that inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF) | |
| CA2458544A1 (en) | Crystals of hydroxynorephedrine derivative | |
| CA2572743A1 (en) | Methods for improving bioavailability of a renin inhibitor | |
| CA2562992A1 (en) | Probucol analogues, and use thereof as anti-inflammatory inhibitors of vcam-1 | |
| US6610739B2 (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
| RU2008138749A (en) | CAMPTOTECINE DERIVATIVES AND THEIR APPLICATION | |
| US20230382840A1 (en) | Anti-inflammatory compounds | |
| JP2003500466A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |